drugset / Trial / NCT05951192

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

NCT05951192

Phase 4 Completed 161 enrolled USRC Kidney Research GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

Investigator-initiated, interventional, prospective study to assess the clinical and operational effectiveness of daprodustat in adult patients receiving in center hemodialysis or peritoneal home dialysis who are transitioning from Mircera to daprodustat.

Timeline

Start
2023-07-01
Primary completion
2024-02-14
Completion
2024-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Daprodustat Small molecule 1 mg Oral
Subject Daprodustat Small molecule 2 mg Oral
Subject Daprodustat Small molecule 4 mg Oral
Subject Daprodustat Small molecule 6 mg Oral
Subject Daprodustat Small molecule 8 mg Oral